Characteristics of severe asthma patients on biologics: a real-life European registry study.

Stefania Principe Levi B Richards Simone Hashimoto Johannes Anthon KroesJob J M H Van BragtSusanne J VijverbergJacob K SontNicola ScichiloneKristina BieksieneAnneke Ten BrinkeZsuzsanna CsomaBarbro DahlénBilun GemiciogluIneta GrislePiotr KunaZorica LazicFlorin MihaltanSanja Popović-GrleSabina ŠkrgatAlessandro MarconMarco CaminatiRatko DjukanovicCeleste PorsbjergAnke-Hilse Maitland Van Der Zee

Published in: ERJ open research (2023)

A large proportion of patients in the SHARP registry would not have been eligible for anti-IL5(R) treatment in RCTs, demonstrating the importance of real-life cohorts in describing the efficacy of biologics in a broader population of patients with severe asthma.

Keyphrases

ejection fraction
newly diagnosed
end stage renal disease
prognostic factors
patient reported outcomes
replacement therapy